BioXcel Therapeutics (BTAI)
(Delayed Data from NSDQ)
$2.63 USD
+0.02 (0.77%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.61 -0.02 (-0.76%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
BTAI 2.63 +0.02(0.77%)
Will BTAI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BTAI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for BTAI
Hold Rating on Bioxcel Therapeutics Amid Strategic and Clinical Trial Uncertainties
Buy Rating Reaffirmed for BioXcel Therapeutics Amidst Expansion Opportunities and FDA-Approved IGALMIā¢
Bioxcel Therapeutics Advances SERENITY Trial and Strategy
BioXcel announces plan for evaluating BXCL501 in at-home setting
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Unity Biotechnology (UBX)